查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602719

类淀粉沉积症治疗市场：按类型、最终用户划分 - 2025-2030 年全球预测

Amyloidosis Treatment Market by Type (Medication, Surgery), End-Users (Hospitals, Specialty Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

类淀粉沉积症治疗市场2023年估值为52.3亿美元，预计2024年将达57.3亿美元，复合年增长率为7.57%，预计到2030年将达到87.3亿美元。

类淀粉沉积症治疗是指用于控制类淀粉沉积症的策略和治疗方法，淀粉样变性是一种罕见疾病，其特征是淀粉样蛋白在器官和组织中异常累积。类淀粉沉积症治疗的范围包括药物治疗、干细胞移植和支持性治疗，每种治疗的目的都是控制症状、减缓疾病进展和改善生活品质。这些治疗的必要性在于类淀粉沉积症能够针对多种类淀粉沉积症，这些淀粉样变性会影响心臟、肾臟、肝臟和神经系统等器官，例如 AL 和 ATTR类淀粉沉积症。治疗应用范围从医疗设施到居家医疗，最终用途包括医院、专科诊所和研究机构。市场成长主要是由药物研究的进步、对罕见疾病的认识提高以及诊断技术的改进所推动的。特别是，随着最近创新治疗方法（例如基于RNA干扰的治疗方法）的激增，新型治疗方法和个人化医疗方法的开发存在重大潜在机会。然而，由于治疗成本上升、疾病管理复杂性和疾病稀有性等挑战，市场扩张受到限制。新创新的机会包括基因研究的进步，以便更好地了解疾病发病机制，以及开发用于早期诊断和治疗监测的更有效的生物标记。此外，虽然市场本质上是利基市场，但持续的研究和投资已经产生了显着的成果，为能够提供具有成本效益和创新解决方案的新进入者铺平了道路。创新的重点领域包括增强药物传输系统、探索联合治疗以及利用人工智慧对治疗结果进行预测分析。为了实现最佳业务成长，建议与监管机构合作，加速药物核准并建立研发策略伙伴关係，并加强意识和早期诊断倡议，促进与医疗保健提供者的合作关係也很重要。

主要市场统计
基准年[2023] 52.3亿美元
预测年份 [2024] 57亿美元
预测年份 [2030] 87.3亿美元
复合年增长率（%） 7.57%

市场动态：揭示快速发展的类淀粉沉积症治疗市场的关键市场洞察

类淀粉沉积症治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助组织做出明智的投资决策、改善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 类淀粉沉积症在大量且不断增长的人群中显着流行
    • 提高对早期诊断和类淀粉沉积症治疗的认识
    • 积极的研究活动开发新的类淀粉沉积症疗法
  • 市场限制因素
    • 类淀粉沉积症药物的高成本和报销政策问题
  • 市场机会
    • 类淀粉沉积症治疗新治疗方法的出现
    • 加大对现代化医疗基础设施的投资
  • 市场挑战
    • 类淀粉沉积症治疗的复杂性与风险

波特的五力：驾驭类淀粉沉积症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解类淀粉沉积症治疗市场的外部影响

外部宏观环境因素在塑造类淀粉沉积症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解类淀粉沉积症治疗市场的竞争格局

类淀粉沉积症治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵淀粉类淀粉沉积症治疗市场供应商的绩效评估

FPNV定位矩阵是评估类淀粉沉积症治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了类淀粉沉积症治疗市场的成功之路

类淀粉沉积症治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于人口成长，类淀粉沉积症盛行率不断增加
      • 提高对类淀粉沉积症早期诊断和治疗的认识
      • 旨在开发类淀粉沉积症新治疗药物的积极研究活动
    • 抑制因素
      • 类淀粉沉积症治疗的高费用和报销政策问题
    • 机会
      • 类淀粉沉积症治疗新治疗选择的出现
      • 加大现代化医疗基础建设投入
    • 任务
      • 类淀粉沉积症治疗的复杂性与风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章类淀粉沉积症治疗市场：按类型

  • 药物治疗
    • 化疗
    • 标靶治疗
      • 抗血管新生治疗
      • 单株抗体
      • 蛋白酶体抑制剂
  • 外科手术
    • 骨髓移植/干细胞移植
    • 器官移植

第七章类淀粉沉积症治疗市场：依最终使用者分类

  • 医院
  • 专业中心

第八章美洲类淀粉沉积症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区类淀粉沉积症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲类淀粉沉积症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie, Inc.
  • Acrotech Biopharma, Inc
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals Inc.
  • Arcturus Therapeutics, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Attralus, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Corino Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc
  • Merck & Co., Inc.
  • Neurimmune AG
  • Oncopeptides AB
  • Pfizer Inc.
  • Proclara Biosciences Inc.
  • Prothena Corporation PLC
  • Regeneron Pharmaceuticals Inc.
  • SOM INNOVATION BIOTECH, SA,
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market was valued at USD 5.23 billion in 2023, expected to reach USD 5.70 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 8.73 billion by 2030.

Amyloidosis treatment refers to the strategies and therapies employed to manage amyloidosis, a rare disease characterized by abnormal accumulation of amyloid proteins in organs and tissues. The scope of amyloidosis treatment involves modalities such as medication, stem cell transplantation, and supportive care, each tailored to manage symptoms, slow disease progression, and improve quality of life. The necessity of these treatments is underscored by their ability to target diverse forms of amyloidosis, addressing conditions like AL amyloidosis and ATTR amyloidosis, which can affect organs including the heart, kidneys, liver, and nervous system. Applications of treatment extend from healthcare facilities to home care, with end-use spanning hospitals, specialty clinics, and research institutes. Market growth is influenced significantly by advances in pharmaceutical research, increasing awareness about rare diseases, and improved diagnostic methodologies. Key potential opportunities reside in the development of novel therapeutics and personalized medicine approaches, particularly as recent innovations such as RNA interference-based therapies gain traction. However, the market faces challenges such as high costs of treatment, the complexity of disease management, and the rarity of the condition, which limits broad market expansion. Emerging opportunities for innovation include advancements in genetic research to better understand the disease pathogenesis and the development of more effective biomarkers for early diagnosis and treatment monitoring. Further, the market's nature remains niche yet marked by significant ongoing research and investment, paving the way for new entrants who can bring cost-effective, innovative solutions. Focus areas for innovation include enhancing drug delivery systems, exploring combination therapies, and harnessing artificial intelligence for predictive analytics in treatment outcomes. For optimal business growth, aligning with regulatory pathways to expedite drug approvals and forming strategic partnerships for research and development are recommended, alongside fostering collaborations with healthcare providers to enhance awareness and early diagnosis initiatives.

KEY MARKET STATISTICS
Base Year [2023] USD 5.23 billion
Estimated Year [2024] USD 5.70 billion
Forecast Year [2030] USD 8.73 billion
CAGR (%) 7.57%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyloidosis Treatment Market

The Amyloidosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant prevalence of amyloidosis among rising gigantic population
    • Growing awareness about early diagnosis and amyloidosis treatments
    • Robust research activities to develop novel amyloidosis drugs
  • Market Restraints
    • Issues related to high cost and reimbursement policies of amyloidosis treatments
  • Market Opportunities
    • Emergence of new treatment options for treating amyloidosis
    • Rising investments to develop modernized healthcare infrastructure
  • Market Challenges
    • Complexities and risk associated with amyloidosis treatments

Porter's Five Forces: A Strategic Tool for Navigating the Amyloidosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyloidosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyloidosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyloidosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyloidosis Treatment Market

A detailed market share analysis in the Amyloidosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyloidosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyloidosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyloidosis Treatment Market

A strategic analysis of the Amyloidosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyloidosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acrotech Biopharma, Inc, Alexion Pharmaceuticals, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Attralus, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Corino Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Merck & Co., Inc., Neurimmune AG, Oncopeptides AB, Pfizer Inc., Proclara Biosciences Inc., Prothena Corporation PLC, Regeneron Pharmaceuticals Inc., SOM INNOVATION BIOTECH, SA,, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Amyloidosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Medication and Surgery. The Medication is further studied across Chemotherapy and Targeted therapy. The Targeted therapy is further studied across Anti-Angiogenesis Therapy, Monoclonal Antibodies, and Proteasome Inhibitors. The Surgery is further studied across Bone Marrow Transplantation/Stem Cell Transplantation and Organ Transplantation.
  • Based on End-Users, market is studied across Hospitals and Specialty Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of amyloidosis among rising gigantic population
      • 5.1.1.2. Growing awareness about early diagnosis and amyloidosis treatments
      • 5.1.1.3. Robust research activities to develop novel amyloidosis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Issues related to high cost and reimbursement policies of amyloidosis treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of new treatment options for treating amyloidosis
      • 5.1.3.2. Rising investments to develop modernized healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities and risk associated with amyloidosis treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amyloidosis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Chemotherapy
    • 6.2.2. Targeted therapy
      • 6.2.2.1. Anti-Angiogenesis Therapy
      • 6.2.2.2. Monoclonal Antibodies
      • 6.2.2.3. Proteasome Inhibitors
  • 6.3. Surgery
    • 6.3.1. Bone Marrow Transplantation/Stem Cell Transplantation
    • 6.3.2. Organ Transplantation

7. Amyloidosis Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Centers

8. Americas Amyloidosis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Amyloidosis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Amyloidosis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Acrotech Biopharma, Inc
  • 3. Alexion Pharmaceuticals
  • 4. Alnylam Pharmaceuticals Inc.
  • 5. Arcturus Therapeutics, Inc.
  • 6. Astellas Pharma, Inc.
  • 7. AstraZeneca PLC
  • 8. Attralus, Inc.
  • 9. BridgeBio Pharma, Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. Corino Therapeutics, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Ionis Pharmaceuticals, Inc.
  • 14. Johnson & Johnson Services Inc
  • 15. Merck & Co., Inc.
  • 16. Neurimmune AG
  • 17. Oncopeptides AB
  • 18. Pfizer Inc.
  • 19. Proclara Biosciences Inc.
  • 20. Prothena Corporation PLC
  • 21. Regeneron Pharmaceuticals Inc.
  • 22. SOM INNOVATION BIOTECH, SA,
  • 23. Sorrento Therapeutics, Inc.
  • 24. Spectrum Pharmaceuticals, Inc.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMYLOIDOSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMYLOIDOSIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ANTI-ANGIOGENESIS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANTATION/STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023